Reply: Post-COVID-19 Myoclonus-Ataxia Syndrome-Is there Really a Need for Intravenous Immunoglobulin Treatment in all Cases?

Massimiliano Godani¹, Alessandro Beronio¹, Giuseppe Lanza^{2

3}

Affiliations

¹ Department of Neurology Sant'Andrea Civic Hospital, ASL 5 Spezzino La Spezia Italy.
² Department of Surgery and Medical-Surgical Specialties University of Catania Catania Italy.
³ Clinical Neurophysiology Research Unit Oasi Research Institute-IRCCS Troina Italy.

Massimiliano Godani et al. Mov Disord Clin Pract. 2023.

. 2023 Mar 25;10(4):726-727.

doi: 10.1002/mdc3.13693. eCollection 2023 Apr.

Massimiliano Godani¹, Alessandro Beronio¹, Giuseppe Lanza^{2

3}

¹ Department of Neurology Sant'Andrea Civic Hospital, ASL 5 Spezzino La Spezia Italy.
² Department of Surgery and Medical-Surgical Specialties University of Catania Catania Italy.
³ Clinical Neurophysiology Research Unit Oasi Research Institute-IRCCS Troina Italy.

No abstract available

Keywords: SARS‐CoV‐2 infection; ataxia; immunoglobulin; myoclonus; post‐COVID‐19.

References

1. Filip P, Jarosław S. Post‐COVID‐19 myoclonus‐ataxia syndrome—Is there really a need for intravenous immunoglobulin treatment in all cases? Mov Dis Clin Pract 2023;10(4):724–725. doi:10.1002/mdc3.13695 - DOI - PMC - PubMed
1. Schneider SA, Hennig A, Martino D. Relationship between COVID‐19 and movement disorders: a narrative review. Eur J Neurol 2022;29(4):1243–1253. - PubMed
1. Przytuła F, Błądek S, Sławek J. Two COVID‐19‐related video‐accompanied cases of severe ataxia‐myoclonus syndrome. Neurol Neurochir Pol 2021;55(3):310–313. - PubMed
1. Godani M, Beronio A, Lanza G. Post‐COVID‐19 myoclonus‐ataxia syndrome responsive to intravenous immunoglobulins. Mov Dis Clin Pract 2022;9(S2):S6–S8. - PMC - PubMed
1. Muccioli L, Pensato U, Bernabè G, et al. Intravenous immunoglobulin therapy in COVID‐19‐related encephalopathy. J Neurol 2021;268(8):2671–2675. - PMC - PubMed